3,978 reports of this reaction
2.2% of all TACROLIMUS OINTMENT 0.1% reports
#7 most reported adverse reaction
TRANSPLANT REJECTION is the #7 most commonly reported adverse reaction for TACROLIMUS OINTMENT 0.1%, manufactured by Encube Ethicals, Inc.. There are 3,978 FDA adverse event reports linking TACROLIMUS OINTMENT 0.1% to TRANSPLANT REJECTION. This represents approximately 2.2% of all 181,625 adverse event reports for this drug.
TACROLIMUS OINTMENT 0.1% has an overall safety score of 92 out of 100. Patients taking TACROLIMUS OINTMENT 0.1% who experience transplant rejection should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TRANSPLANT REJECTION is a less commonly reported adverse event for TACROLIMUS OINTMENT 0.1%, but still significant enough to appear in the safety profile.
In addition to transplant rejection, the following adverse reactions have been reported for TACROLIMUS OINTMENT 0.1%:
The following drugs have also been linked to transplant rejection in FDA adverse event reports:
TRANSPLANT REJECTION has been reported as an adverse event in 3,978 FDA reports for TACROLIMUS OINTMENT 0.1%. This does not prove causation, but indicates an association observed in post-market surveillance data.
TRANSPLANT REJECTION accounts for approximately 2.2% of all adverse event reports for TACROLIMUS OINTMENT 0.1%, making it a notable side effect.
If you experience transplant rejection while taking TACROLIMUS OINTMENT 0.1%, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.